Alivus Life Sciences Limited
ICICI Prudential Mutual Fund, which previously held a 1.28 percent stake in Alivus Life Sciences Limited, is no longer listed among the company's disclosed shareholders, indicating either a complete sale or a reduction to below the 1 percent reporting threshold.
A specialized pharmaceutical manufacturer focused on developing and producing high-value active pharmaceutical ingredients for chronic disease treatments across multiple therapeutic areas. Operating as a subsidiary of Nirma Limited, a diversified conglomerate, the company serves global specialty pharmaceutical companies through contract development and manufacturing services. Its distinctive strength lies in producing non-commoditized APIs where technical expertise, regulatory compliance, and quality standards are paramount.
India's second-largest AMC by AUM with over Rs 9 lakh crore managed across 80+ schemes. Joint venture between ICICI Bank and Prudential plc. CIO S. Naren is one of India's most recognised value investors, known for contrarian macro calls and rotating across market caps well ahead of consensus. ICICI Pru's quarterly portfolio disclosures are among the most closely watched in the industry.